{"id":"ono-5920","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Jaw pain"},{"rate":null,"effect":"Flushing"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ONO-5920 selectively binds to and activates prostanoid IP receptors, which are G-protein coupled receptors involved in vascular homeostasis and platelet function. By agonizing these receptors, the drug increases intracellular cAMP levels, leading to vasodilation and suppression of platelet activation. This mechanism is intended to improve blood flow and reduce thrombotic events in cardiovascular conditions.","oneSentence":"ONO-5920 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:23.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"},{"name":"Chronic thromboembolic pulmonary hypertension"}]},"trialDetails":[{"nctId":"NCT05645289","phase":"PHASE4","title":"Efficacy and Safety of Minodronate in Patients With Low Back Pain","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-01-01","conditions":"Postmenopausal Osteoporosis","enrollment":72},{"nctId":"NCT05305183","phase":"PHASE3","title":"A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-05-31","conditions":"Osteoporosis","enrollment":330},{"nctId":"NCT00794443","phase":"PHASE2, PHASE3","title":"ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-11","conditions":"Osteoporosis, Bone Loss, Age-Related","enrollment":692},{"nctId":"NCT02295436","phase":"PHASE1","title":"Pharmacokinetics and Tolerability of Minodronic Acid and Food and Age Effects on the Pharmacokinetics","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2014-08","conditions":"Osteoporosis","enrollment":48},{"nctId":"NCT00212719","phase":"PHASE3","title":"Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2003-05","conditions":"Involutional Osteoporosis","enrollment":250},{"nctId":"NCT00212667","phase":"PHASE3","title":"Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2002-08","conditions":"Involutional Osteoporosis","enrollment":650},{"nctId":"NCT00212628","phase":"PHASE3","title":"Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2004-06","conditions":"Involutional Osteoporosis","enrollment":444},{"nctId":"NCT00965978","phase":"PHASE1","title":"A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-07","conditions":"Osteoporosis, Osteoporosis, Postmenopausal, Bone Diseases","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ONO-5920","genericName":"ONO-5920","companyName":"Ono Pharmaceutical Co. Ltd","companyId":"ono-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ONO-5920 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation. Used for Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}